Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 29.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
constipation, diarrhoea, dietary fibre supplement
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Lactitol (Loozfibre) is a sugar alcohol used as a replacement bulk sweetener for low calorie foods with approximately 40% of the sweetness of sugar
Usual dosage is one measure at bedtime or as directed by the physician.
2.1 Recommended Dosage
- The recommended adult dosage of Lactitol (Loozfibre) is 20 grams orally once daily, preferably with meals.
- Reduce the dosage to 10 grams once daily for persistent loose stools.
- Administer oral medications at least 2 hours before or 2 hours after Lactitol (Loozfibre).
2.2 Preparation and Administration Instructions
Lactitol (Loozfibre) Multi-dose bottle
NOTE: The bottle top is a measuring cap marked to contain 10 grams of powder when filled to the top of white section in the cap marked by the arrow.
- Using the measuring cap, measure the prescribed dose.
- 20-gram dose: Fill the measuring cap twice to the top of the white section in cap marked by the arrow.
- 10-gram dose: Fill the measuring cap once to the top of the white section in cap marked by the arrow.
- Pour the measured dose into an empty 8-ounce glass.
- Add 4 ounces to 8 ounces of water, juice or other common beverages (coffee, tea, soda) and stir to dissolve.
- Drink the entire contents of the glass.
Lactitol (Loozfibre) Unit-dose packets
- Pour the contents of one or two unit-dose packets, as prescribed, into an empty 8-ounce glass.
- Add 4 ounces to 8 ounces of water, juice or other common beverages (coffee, tea, soda) to the glass containing the powder and stir thoroughly to dissolve.
- Drink the entire contents of the glass.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Lactitol (Loozfibre) is contraindicated in patients with:
- known or suspected mechanical gastrointestinal obstruction
- galactosemia
Used for the treatment and management of constipation including pregnancy-associated constipation, hemorrhoids, anal fissures, diverticular disease, ulcerative colitis and inflammatory bowel syndrome.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Lactitol (Loozfibre) is used for the treatment of constipation and prevention of hepatic encephalopathy (decline in brain function as a result of severe liver disease).
Dichlorphenamide: Laxatives may enhance the hypokalemic effect of Dichlorphenamide. Monitor therapy
Abdominal bloating, Flatulence, Intestinal obstruction, Gastrointestinal discomfort
6.1 Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Lactitol (Loozfibre) in 807 patients with CIC in a six-month placebo-controlled trial (Study 1), a three-month active-controlled trial (Study 2), and a one-year uncontrolled safety study (NCT02819310). Of the 298 patients in the one-year uncontrolled study, 55 patients were enrolled from Study 1 or Study 2.
Most Common Adverse Reactions:
Table 1 provides the incidence of adverse reactions in Study 1 reported in at least 3% of patients in the Lactitol (Loozfibre) treatment group and at higher incidence than placebo.
In Study 2, the safety profile of Lactitol (Loozfibre) was similar to study 1.
In the 1-year uncontrolled safety study, adverse reactions reported in patients receiving Lactitol (Loozfibre) (N=298) with an incidence of at least 3% that are not represented in Table 1 include urinary tract infection (5%) and abdominal pain (3%).
Adverse Reaction of Special Interest - Severe Diarrhea
In Study 1, severe diarrhea was reported in 2 (1%) Lactitol (Loozfibre)-treated patients compared to no patients in the placebo group.
Adverse Reactions Leading to Discontinuation
In Study 1, 11/291 (4%) Lactitol (Loozfibre)-treated patients discontinued due to adverse reactions, compared to 10/302 (3%) of patients in the placebo group. The most common adverse reactions leading to discontinuation in Lactitol (Loozfibre)-treated patients (1% each) were elevated creatinine kinase, flatulence, diarrhea and increased blood pressure.
6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Lactitol (Loozfibre) outside of the United States. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- hypersensitivity reactions, including rash and pruritus